52.90
+2.52%
Close of 9 Nov 2026, in DKK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About H Lundbeck A/S
Its shares trade on Nasdaq Copenhagen under the ticker HLUN A.CO. It has been listed since 1 January 1999. In the fiscal year to 31 December 2025, it reported revenue of DKK 24.35bn and net income of DKK 3.19bn. At that date it held total assets of DKK 54.01bn and shareholders' equity of DKK 24.90bn.
H Lundbeck A/S is a DK-based company operating in Pharmaceuticals industry. H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. The company is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The firm operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 1 Jan 1999
- Employees
- 5,700
- Website
- lundbeck.com ↗
Leadership
Pay as last reported
- Dr. Ilse WenzelIndependent Chairman of the BoardDKK 700,000
- Mr. Charl Van ZylPresident, Chief Executive OfficerDKK 27.7m
- Ms. Lene Skole-SoerensenDeputy Chairman of the BoardDKK 1.2m
- Mr. Joerg HornsteinChief Financial Officer, Executive Vice President - Corporate FunctionsDKK 11.2m
- Ms. Dianne HolExecutive Vice President - People and Culture
- Ms. Maria AlfaiateExecutive Vice President - Commercial and Corporate Strategy
- Mr. Lars BangExecutive Vice President - Product Development and Supply, since 2018DKK 10.5m
- Ms. Michala Fischer-HansenExecutive Vice President, Head - Europe and International Operations
- Mr. Thomas GibbsExecutive Vice President, Head of Lundbeck - United States
- Dr. Per LuthmanExecutive Vice President - Research and DevelopmentDKK 11.6m
- Ms. Camilla AnderssonDirector, Employee RepresentativeDKK 400,000
- Mr. Hossein ArmandiDirector, Employee RepresentativeDKK 400,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 74
- Environment
- 80
- Social
- 94
- Governance
- 48
- Direct emissions (scope 1)
- 21,357 t
- Energy emissions (scope 2)
- 15,602 t
- Value chain emissions (scope 3)
- 119,336 t
- Women in the workforce
- 54.5%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- H Lundbeck A/S focuses on brain disorder treatments with Cipralex and Ebixa in the pharmaceuticals industry.
- The company has a strong product portfolio including Azilect for Parkinson's disease and Xenazine for Huntington's disease.
- Lundbeck operates through subsidiaries like Lundbeck SAS and Lundbeck GmbH in multiple countries.
Weaknesses
- H Lundbeck A/S has limited presence in emerging markets compared to global competitors.
- The company relies heavily on a few key products like Cipralex for a significant portion of revenue.
- Lundbeck's employee count of 5700 is smaller than major pharmaceutical firms.
Opportunities
- Expanding into new markets for Alzheimer's treatments like Ebixa could drive growth.
- Increasing demand for mental health treatments presents a significant opportunity.
- The aging population in Europe supports growth for neurological disorder medications.
Threats
- Competition from generic drugs threatens revenue from products like Cipralex.
- Patent expirations for key drugs could reduce market share.
- Regulatory changes in the Health Care sector may increase operational costs.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.